JOURNAL BACTERIOLOGY, Sept. 2000, p. 5147â€“5152                                                                                  Vol. 182,  18
0021-9193/00/$04.00â«¹0
Copyright Â© 2000, American Society Microbiology. Rights Reserved.



          Essentiality, Expression, Characterization Class II
             3-Hydroxy-3-Methylglutaryl Coenzyme Reductase                               Staphylococcus aureus
          E. IMOGEN WILDING,1 DONG-YUL KIM,2 ALEXANDER P. BRYANT,1 MICHAEL N. GWYNN,1*
        R. DWAYNE LUNSFORD,1 DAMIEN MCDEVITT,1 JOSEPH E. MYERS, JR.,1 MARTIN ROSENBERG,1
               DANIEL SYLVESTER,1 CYNTHIA V. STAUFFACHER,3 VICTOR W. RODWELL2
             Department Microbiology, SmithKline Beecham Pharmaceuticals, Collegeville, Pennsylvania 19426,1              Departments Biochemistry2 Biological Sciences,3 Purdue University, West Lafayette, Indiana 47907
                                              Received 21 April 2000/Accepted 12 June 2000

             Sequence comparisons implied presence genes encoding enzymes mevalonate pathway           isopentenyl diphosphate biosynthesis gram-positive pathogen Staphylococcus aureus. study           showed genetic disruption experiments mvaA, encodes putative class II 3-hydroxy-3-
          methylglutaryl coenzyme (HMG-CoA) reductase, essential vitro growth S. aureus. Supplementa-
          tion media mevalonate permitted isolation auxotrophic mvaA null mutant attenuated           virulence murine hematogenous pyelonephritis infection model. mvaA gene cloned S. aureus
          DNA expressed N-terminal tag Escherichia coli. encoded protein affinity purified
          apparent homogeneity shown class II HMG-CoA reductase, class II eubacterial
          biosynthetic enzyme isolated. Unlike HMG-CoA reductases, S. aureus enzyme exhibits dual
          coenzyme specificity NADP(H) NAD(H), NADP(H) preferred coenzyme. Kinetic param-
          eters determined substrates catalyzed reactions using NADP(H) NAD(H).           instances optimal activity using NAD(H) occurred pH units acidic using
          NADP(H). pH profiles suggested His378 Lys263, apparent cognates active-site histidine           lysine Pseudomonas mevalonii HMG-CoA reductase, function catalysis general catalytic
          mechanism valid S. aureus enzyme. Fluvastatin inhibited competitively HMG-CoA, Ki           320 â?®M, 104 higher class HMG-CoA reductase. Bacterial class II HMG-CoA reductases
          potential targets antibacterial agents directed multidrug-resistant gram-positive cocci.


   Isoprenoids, ubiquitous nature, comprise fam-              distinct classes HMG-CoA reductase. Genes appear ily 23,000 products, composed repeating                 encode class HMG-CoA reductases present eu-
carbon, isopentenyl diphosphate (IPP) subunits. principal                karyotes, archaea, streptomycetes. products IPP bacteria include lipid carrier undeca-                contrast, genes encode class II forms enzyme prenol, involved cell wall biosynthesis (33), mena-              present eubacteria archaeon Archaeoglobus
quinones ubiquinones involved electron transport (29),                fulgidus (41). Previously characterized class HMG-CoA  carotenoids (19). pathways biosynthesis IPP               ductases include archaea Haloferax volcanii (6) described, mevalonate pathway (16)                     Sulfolobus solfataricus (7, 22), gram-positive eubacte-
glyceraldehyde-3-phosphate (GAP)-pyruvate pathway (36, 37).                  rium Streptomyces sp. strain CL190 (40), numerous eu-
Analysis distribution genes encoding enzymes                   karyotes. Characterized class II HMG-CoA reductases include
involved pathways revealed Bacillus subtilis              fulgidus (23) biodegradative Pseudomonas gram-negative bacteria, including Escherichia coli, Hae-                mevalonii enzyme (4, 20), structure deter-
mophilus influenzae, Helicobacter pylori, possess genes             mined (24, 39) converts mevalonate HMG-CoA, encode GAP-pyruvate pathway, low-Gâ«¹C                      permitting growth mevalonate (15). biosynthetic eubac-
gram-positive cocci Borrelia burgdorferi possess genes              terial class II HMG-CoA reductase   char- encode mevalonate pathway (41).  func-                  acterized.
tionality implied polypeptides mevalonate path-                   Biosynthetic HMG-CoA reductases catalyze reaction 1, way bacteria demonstrated.                                   reductive deacylation thioester group HMG-CoA    Enzymes involved mevalonate pathway number                 primary alcohol mevalonate using 2 mol NADPH
organisms, including humans, isolated studied.                 (35). putative intermediates, mevaldyl-CoA mevalde-
3-Hydroxy-3-methylglutaryl coenzyme (HMG-CoA) reduc-                       hyde, remain bound course reaction. HMG-
tase (EC 1.1.1.34) best-characterized rate-limiting               CoA reductases catalyze additional reactions. 
enzyme pathway (9) target statin class              actions 2 3 free mevaldehyde appear model cholesterol-lowering drugs (1). Based amino acid se-                   second reductive stage reverse reductive
quence analysis, Bochar et al. (8) suggested              stage reaction 1, respectively. Reaction 4, oxidative ac-
                                                                             ylation (R)-mevalonate (S)-HMG-CoA, reverse                                                                              reaction 1.
  * Corresponding author. Mailing address: Department Microbi-
ology, SmithKline Beecham Pharmaceuticals, 1250 South College Rd.,                å…±Så…²-HMG-CoA â«¹ 2 NADPH â«¹ 2 Hâ«¹3å…±Rå…²-mevalonate â«¹ CoASH â«¹ 2 NADPâ«¹   (1)
Collegeville, PA 19426. Phone: (610) 917-7749. Fax: (610) 917-4989.
E-mail: Mick_Gwynn-1@sbphrd.com.                                                      å…±Rå…²-mevaldehyde â«¹ NADPH â«¹ Hâ«¹3å…±Rå…²-mevalonate â«¹ NADPâ«¹         (2)

                                                                      5147
5148       WILDING ET AL.                                                                                                                               J. BACTERIOL.




   FIG. 1. Chromosomal analysis S. aureus mvaA null mutant.   chromosome mvaA null mutant contains allelic replacement mvaA (dotted
block arrow) ermC gene (gray block arrow). PCR primers (small arrows) designed anneal regions flanking mvaA. (B) Products expected size amplified using chromosomal DNA mutant (2,288 bp [lane 3]) wild type (2,371 bp [lane 8]). Replacement mvaA ermC resulted elimination HindIII sites introduction SspI sites chromosome. Amplified fragments digested HindIII SspI, products expected size obtained. Lane 1, mutant PCR product incubated HindIII (undigested); lane 2, mutant PCR product cut SspI (1,518 659 bp smaller bands); lane 6, wild-type PCR product cut HindIII (894, 776, 618 bp); lane 7, wild-type PCR product incubated SspI (undigested);
lanes 4 5, 100-bp 1-kb DNA markers, respectively.


        å…±Rå…²-mevaldehyde â«¹ NADPâ«¹ â«¹ CoASH3å…±Så…²-HMG-CoA â«¹ NADPH â«¹ Hâ«¹             (3)          Determination essentiality mvaA gene. DNA construct allelic
                                                                                       replacement S. aureus mvaA gene generated overlap piece
       å…±Rå…²-mevalonate â«¹ 2 NADPâ«¹ â«¹ CoASH3å…±Så…²-HMG-CoA â«¹ 2 NADPH â«¹ 2 Hâ«¹         (4)       PCR technique. technique gene fusion procedure (42) extended                                                                                        include separate long flanking sequences (547 bp directly upstream 591 CoASH reduced coenzyme                                                      bp directly downstream mvaA gene) surrounding central selectable
   report mvaA gene gram-positive                              cassette containing 1,234-bp ermC gene pE194 (17). final 
pathogen Staphylococcus aureus essential growth,                         length products digested cloned BamHI site pBluescript
report cloning, purification, characterization                          II KS(â«¹) derivative containing tetracycline resistance gene (tetK) pT181
mvaA gene product S. aureus, truly biosynthetic                           (21). resulting plasmids introduced S. aureus RN4220 electro-
                                                                                       poration selection resistance erythromycin. colonies iso-
class II HMG-CoA reductase characterized eubacterium.                           lated, resistant tetracycline (cointegrants), examined                                                                                        target-specific plasmid integration diagnostic PCR primer pairs based                         MATERIALS METHODS                                          plasmid- locus-specific sequences. Bona fide plasmid cointegrants                                                                                        transferred S. aureus RN4220 NCTC 8325-4 phage â?¾11 trans-
   Reagents. Purchased reagents included restriction enzymes, calf intestinal          duction allow second recombination event potentially resolve
alkaline phosphatase, T4 DNA ligase, protein DNA molecular weight mark-            generate allelic-replacement mutation. Transductants resistant erythromy-
ers (Gibco BRL Life Technologies), Pfu Turbo DNA polymerase (Stratagene),              cin sensitive tetracycline examined allelic replacement PCR. lysostaphin (Applied Microbiology, ). Fluvastatin gift Novar-          Murine hematogenous pyelonephritis infection model. Cells overnight
tis. Unless specified, chemicals Sigma.                  cultures S. aureus NCTC 8325-4 mvaA null mutant grown TSB    Plasmid, bacterial strains, culture media. Expression plasmid pET28         10 mM mevalonate required centrifuged, washed twice sterile phos- Novagen. Bacterial strains used included E. coli BL21(DE3) DH5â?£           phate-buffered saline, adjusted A600 0.2. Female CD-1 mice weigh-
S. aureus strains RN4220 (31), WCUH29 (NCIMB 40771), NCTC 8325-4.                  ing 18 20 g (Charles River, Quebec, Canada) inoculated tail vein
Luria-Bertani broth agar (38) served growth E. coli, tryptone soy       injection 0.2 ml suspension containing approximately 107 bacteria. Mice
broth (TSB) tryptone soy agar (TSA) (Oxoid) served growth S. aureus.        monitored twice daily signs illness. animals euthanatized required, E. coli medium supplemented 50 â?®g kanamycin            carbon dioxide overdose 5 days inoculation. kidneys removed ml 1  (wt/vol) glucose S. aureus medium supplemented          using aseptic technique homogenized 1 ml PBS, 0.5 â?®g erythromycin 5 â?®g tetracycline ml.                                number viable bacteria determined plating TSA, sup-
   DNA techniques. Plasmid DNA isolated using RPM kit (Bio 101 )           plemented 10 mM mevalonate mvaA null mutant. Wizard Midiprep DNA purification (Promega). PCR products                    Construction HMG-CoA reductase expression plasmid. mvaA gene isolated horizontal agarose gel electrophoresis purified using         amplified S. aureus WCUH29 chromosomal DNA using primers GENECLEAN II kit (Bio 101 ). Chromosomal DNA isolated S.                  introduced NheI BamHI sites ends amplified fragment. aureus using standard procedures (27). Incubation 0.1 â?®g lysostaphin       1,278-bp PCR fragment cloned using pCR-Zero Blunt cloning kit  
ml included preparation plasmid chromosomal DNA             vitrogen)  using introduced restriction sites, subcloned pET28 S. aureus facilitate cell lysis. Procedures DNA restriction, dephosphoryla-     frame N-terminal histidine tag thrombin cleavage site form pJO1.
tion ligation, agarose gel electrophoresis, PCR, transformation CaCl2-          insert sequenced verify errors introduced competent E. coli, phage transduction performed described               PCR amplification.
Sambrook et al. (38) recommended manufacturersâ€™ instructions. PCR            Expression purification HMG-CoA reductase. E. coli BL21(DE3) cells
employed RoboCycler gradient temperature cycler (Stratagene). Synthetic              containing pJO1 grown mid-log phase, induced addition 1 mM
oligonucleotides prepared, automated DNA sequencing                   isopropyl-â?¤-D-thiogalactopyranoside (IPTG), harvested 2.5 h postinduction.
formed house SmithKline Beecham.                                                 confirm expression, total cell lysates prepared outlined Sambrook
VOL. 182, 2000                                                                        STAPHYLOCOCCUS AUREUS HMG-CoA REDUCTASE                                       5149


                                                                                         Reaction 1, reductive deacylation HMG-CoA mevalonate. Assays using
                                                                                      NADPH coenzyme contained 0.25 mM NADPH, 0.25 mM (R,S)-HMG-
                                                                                      CoA, 50 mM NaCl, 1 mM EDTA, 5 mM DTT, 25 mM KH2PO4 (pH 7.5).
                                                                                      Assays using NADH coenzyme contained 0.25 mM NADH, 0.25 mM
                                                                                      (R,S)-HMG-CoA, 50 mM NaCl, 1 mM EDTA, 5 mM DTT, 25 mM KH2PO4
                                                                                      (pH 6.0).
                                                                                         Reaction 2, reduction mevaldehyde mevalonate. Assays contained 0.5
                                                                                      mM NADPH, 8.0 mM (R,S)-mevaldehyde, 50 mM NaCl, 1 mM EDTA, 5 mM
                                                                                      DTT, 25 mM KH2PO4 (pH 7.0).
                                                                                         Reaction 3, oxidative acylation mevaldehyde HMG-CoA. Assays 
                                                                                      tained 0.5 mM NADPâ«¹, 5.0 mM coenzyme  8.0 mM (R,S)-mevaldehyde, 50
                                                                                      mM NaCl, 1 mM EDTA, 5 mM DTT, 100 mM Tris-HCl (pH 9.0).
                                                                                         Reaction 4, oxidative acylation mevalonate HMG-CoA. Assays contained
                                                                                      5 mM NADPâ«¹, 5.0 mM coenzyme  6.0 mM (R,S)-mevalonate, 50 mM NaCl,
                                                                                      1 mM EDTA, 5 mM DTT, 100 mM Tris-HCl (pH 9.0).
                                                                                         Unless stated, reactions initiated adding HMG-CoA,
   FIG. 2. Expression S. aureus mvaA purification gene product.       mevaldehyde, mevalonate. assays, enzyme unit represents protein anticipated size absent induced E. coli BL21(DE3) cells       turnover, 1 min, 1 â?®mol nicotinamide nucleotide coenzyme. corre-
containing parent vector (lane 1) expressed cells containing pJO1      sponds turnover 1 â?®mol mevaldehyde 0.5 â?®mol HMG-CoA
(lane 2). Lane 3, crude cytosol; lane 4, material failed bind nickel   mevalonate. Reported data mean values triplicate determinations.
column. Bound protein eluted imidazole concentrations 10 mM
(lane 5), 50 mM (lane 6), 100 mM (lane 7), 500 mM (lane 8). Lanes 9 10 contain 20 4 â?®g purified protein, respectively.                                                               RESULTS

                                                                                         Essentiality mvaA gene S. aureus. genes 
et al. (38) subjected sodium dodecyl sulfate-polyacrylamide gel electro-       volved synthesis IPP mevalonate pathway phoresis. Purification HMG-CoA reductase employed 500-ml culture              essential vitro growth Streptococcus pneumoniae (41).
E. coli BL21(DE3) transformed pJO1. Following induction, cells harvested centrifugation HMG-CoA reductase purified using                                                                                        determine S. pneu-
HisTrap kit (Amersham Pharmacia Biotech) essentially described              moniae representative gram-positive cocci manufacturerâ€™s instructions, following modifications. Cell lysis     HMG-CoA reductase essential pathogens. Attempts
performed addition 0.2 mg lysozyme ml incubation 20 min          delete mvaA chromosome S. aureus 37Â°C. Lysates frozen dry ice-ethanol bath, thawed, sonicated times 10 s, 10 s bursts. freezing sonication
                                                                                      using allelic-replacement mutagenesis strategy. non-
procedure repeated times. Protein eluted column 10,        essential genes cointegrant readily resolved using
50, 100, 500 mM imidazole. Purified HMG-CoA reductase solution            phage transduction isolate mutant fre-
50 mM KH2PO4 (pH 7.5), 200 mM NaCl, 1 mM dithiothreitol (DTT), 1 mM                   quency 0.5 5 . case,  proved impossible
EDTA, 50  (wt/vol) glycerol stored â«º20Â°C. Protein concentrations determined using Bradford assay (10) using bovine serum albumin                                                                                       resolve cointegrant structure isolate mutant standard.                                                                           standard growth media, strongly suggesting mvaA es-
  Assays HMG-CoA reductase activities. Spectrophotometric assays HMG-           sential vitro growth.
CoA reductase activity employed Hewlett-Packard model 8452 diode array                 growth media supplemented meval-
spectrophotometer cell compartment maintained 37Â°C mea-
surements 340 nm oxidation reduction NAD(P)H. Assays                                                                                       onate, mvaA auxotrophic mutants readily obtained conducted final volume 200 â?®l. Standard assay conditions             allelic replacement confirmed using diagnostic PCR
reaction studied follows.                                                     restriction analysis. Oligonucleotide primers designed 



   FIG. 3. Effect hydrogen ion concentration activity. effects indicated concentrations hydrogen ion rates indicated reactions assayed standard conditions pH using NADP(H) (F) NAD(H) (E) coenzyme. Assays conducted solution 50 mM KCl,
25 mM K-PO4, 100 mM Tris-HCl adjusted indicated pH values (x axis).  left) Reaction 1, reductive deacylation HMG-CoA mevalonate;  right)
reaction 2, reduction mevaldehyde mevalonate; (lower left) reaction 3, oxidative acylation mevaldehyde HMG-CoA; (lower right) reaction 4, oxidative
acylation mevalonate HMG-CoA. eu, enzyme units.
5150         WILDING ET AL.                                                                                                                           J. BACTERIOL.


      TABLE 1. Comparison Km values class II S. aureus
      HMG-CoA reductase class II biodegradative
         enzyme P. mevalonii class biosynthetic
                         hamster enzymea
                                                       Km (â?®M) enzyme 
             Reaction substrates                   S.         P.
                                                                             Hamster
                                                     aureus    mevalonii

Reaction 1 (HMG-CoA3mevalonate)
 HMG-CoA                                                40         20            20
 NADPH                                                  70                       80
 NADH                                                  100         80

Reaction 2 (mevaldehyde3mevalonate)
 Mevaldehyde                                         6,900      8,000         1,600
 NADPH                                                 240                      160
                                                                                          FIG. 4. Inhibition statin drug. Double-reciprocal plot inhibition Reaction 3 (mevaldehyde3HMG-CoA)                                                       reaction 1, reductive deacylation HMG-CoA mevalonate, using
 Mevaldehyde                                           570         80            90    NADPH coenzyme. Analyses conducted pH 7.5 37Â°C                                                                                        indicated concentrations HMG-CoA presence 0 â?®M (E) 500 â?®M
 CoASH                                                 490        110            50    (F) fluvastatin. reactions initiated adding NADPH. eu, enzyme units.
 NADPâ«¹                                                  40                      600

Reaction 4 (mevalonate3HMG-CoA)
 Mevalonate                                            670        260            20
 CoASH                                                 390         60            10    mevalonate concentration reduced 1 nM, 
 NADPâ«¹                                                 580                      510    mvaA null mutant unable grow, viability
                                                                                       unaffected (data shown).
        Data P. mevalonii hamster HMG-CoA reductase reference              Virulence attenuation mvaA null mutant. mvaA
34.
                                                                                       mutation transferred pathogenic strain S. aureus
                                                                                       NCTC 8325-4 phage â?¾11 transduction. resulting mu-
                                                                                       tants auxotrophic mevalonate. mice inocu-
anneal regions flanking mvaA (Fig. 1) internal                         lated intravenously S. aureus NCTC 8325-4 regions mvaA ermC (data shown) used                               mvaA null mutant sacrificed 5 days postinfection  plify chromosomal DNA templates prepared wild-                                mice died infection). Viable S. aureus NCTC
type mutant strains. expected products obtained,                          8325-4 harboring deletion recovered confirming mvaA replaced ermC auxo-                            kidneys  e., level limit detection 1.6
trophic mutant.                                                                        log10 CFU/mouse) plated presence mevalonate,
   Auxotrophy mvaA null mutants. minimal concentra-                             contrast wild type, S. aureus NCTC 8325-4, tion mevalonate required growth S. aureus                            present 5.17 â«¾ 0.17 log10 CFU/mouse (mean â«¾ standard
mvaA null mutant investigated TSA containing meval-                             deviation mice). results indicate auxotro-
onate 0.01, 0.1, 1 mM TSA supplemen-                             phic mvaA null mutant greatly reduced virulence tation. Addition mevalonate medium enabled                               hematogenous pyelonephritis infection model.
mutant grow, rate growth lower lower                            Expression mvaA purification S. aureus HMG-CoA
concentrations mevalonate. absence added                               reductase. mvaA gene S. aureus cloned pET28
valonate, mutant showed growth 60 h rich                               frame N-terminal histidine tag thrombin cleav-
medium (TSA).                                                                          age site. soluble protein expressed E. coli BL21(DE3)
   minimum concentration mevalonate required                             high levels following induction 1 mM IPTG mvaA null mutant overnight growth TSB 1 mM (data                            readily purified nickel-chelating column, majority shown). effect removing mevalonate                              eluting 500 mM imidazole fraction (Fig. 2). Typical
dium viability mvaA null mutants investigated.                           yields 30 mg 90  homogenous protein liter overnight culture mvaA null mutant grown                              induced culture. mvaA gene encodes putative protein presence 1 mM mevalonate diluted 106-fold fresh                            425 residues calculated molecular weight 46,180.
media mevalonate. number viable                                Matrix-assisted laser desorption ionization mass spectrometry
cells determined plating presence 1 mM                                analysis indicated purified protein molecular
mevalonate. presence mevalonate mutant grew                              weight 48,503, corresponds length HMG-  viable count increased 4 logs 24 h.                         CoA reductase fusion protein minus terminal methionine
                                                                                       residue. N-terminal sequencing purified protein 
                                                                                       firmed residue removed N-
TABLE 2. Relative abilities class II HMG-CoA reductases                       terminal sequence intact.
               use NADP(H) NAD(H)                                                  Biochemical characterization. enzymatic activity                                                                                        purified protein determined measuring oxidation  Source                     kcat(NADPH)/kcat(NADH) fora:
 HMG-CoA                                                                   Reference
                                                                                       reduction NAD(P)H 340 nm. Firstly, temperature
  reductase              Reaction 1               Reaction 4                           dependency S. aureus HMG-CoA reductase deacy-
                                                                                       lation HMG-CoA investigated. Optimal activity S. aureus                      25                   25                  study     catalysis reaction 1 observed 35 45Â°C  fulgidus                     0.5                  0.05               23             decreased precipitously 45Â°C (data shown). sub-
P. mevalonii                                     4.4 â«» 10â«º4             14
                                                                                       sequent assays conducted 37Â°C.
        kcat, turnover number.                                                              Coenzyme specificity S. aureus HMG-CoA reductase VOL. 182, 2000                                                                    STAPHYLOCOCCUS AUREUS HMG-CoA REDUCTASE                                 5151




  FIG. 5. Alignment selected amino acid sequences class II HMG-CoA reductases S. aureus (Sa) P. mevalonii (Pm). Conserved paired residues
E81S-E83P, K263S-K267P, D279S-D283P, H378S-H381P, bold, represent active-site residues known function catalysis P. mevalonii enzyme. conserved ENVIG, DAMGXN, GTVGG sequences shaded. Asp146P Leu148P, marked asterisks, contribute ability P. mevalonii HMG-CoA
reductase discriminate NADP(H). Additional residues conserved sequences boxed. sequences S. aureus P. mevalonii
HMG-CoA reductases 39  identical overall. Alignment performed using MegAlign sequence analysis software DNASTAR , Madison, Wis.



investigated range pH values. Figure 3 illustrates                  reductase established functions catalysis (9). pH profiles catalysis reactions 1 4 using                        infer mechanism proposed catalysis NADP(H) NAD(H) coenzyme. Unlike                              P. mevalonii HMG-CoA reductase (39) valid S. aureus
characterized HMG-CoA reductases, S. aureus enzyme                        HMG-CoA reductase.
use NADP(H) NAD(H) coenzymes catalysis                            characterized class II HMG-CoA reductases use reactions. significant activity observed using                 NAD(H) (Table 2), S. aureus  fulgidus
NAD(H), NADP(H) instances preferred coen-                          enzymes use NAD(P)H NAD(H). respect, zyme. reactions, optimal activity using NAD(H)                       S. aureus enzyme closely resembles archaeal enzyme
occurred pH units acidic using                     mesophilic, biodegradative counterpart. ability NADP(H).                                                                          S. aureus HMG-CoA reductase use coenzyme    Km values determined substrates                      predicted, Asp146P Leu148P major determinants
reactions catalyzed HMG-CoA reductases. Table 1 summa-                         nucleotide coenzyme specificity P. mevalonii HMG-CoA
rizes data includes comparison Km values                   reductase (14). Crystal structures P. mevalonii enzyme class II HMG-CoA reductase P. mevalonii                         revealed Asp146P interacts 2â¬˜-hydroxyl class Syrian hamster enzyme. Table 2 coenzyme spec-                      adenosyl ribose NAD(H), discriminating NADP(H)
ificities characterized class II HMG-CoA reduc-                      (24, 39). Consistent ability use NADP(H), sequence
tases compared.                                                               alignments revealed clear cognates Asp146P Leu148P
   effect statin drug fluvastatin S. aureus HMG-                    S. aureus HMG-CoA reductase. Despite significant similar-
CoA reductase investigated. Statin drugs competitive                      ity (39  identity 57  similarity), ability S. aureus
inhibitors HMG-CoA reductase activity (9), ex-                          HMG-CoA reductase accommodate coenzymes sug-
pected, catalysis reaction 1 inhibited fluvastatin.                     gests significant differences coenzyme binding site
Inhibition competitive respect HMG-CoA,                        apparent crystal structure S. aureus
Ki 320 â?®M (Fig. 4).                                                            HMG-CoA reductase determined compared                                                                                   P. mevalonii enzyme. Finally, suggest ability                          DISCUSSION                                               use coenzymes turn general property    demonstrated mvaA gene essential                        biosynthetic class II forms enzyme.
growth S. aureus mvaA null mutants                              Despite ability use NAD(H), S. aureus HMG-CoA
readily isolated media supplemented mevalonate.                           reductase true biosynthetic enzyme. inferred results support previous observations mvaA es-                      preference NADPH presence S. aureus sential S. pneumoniae (41) strongly suggest gene                  genes encode putative HMG-CoA synthase, mevalonate essential gram-positive cocci use meval-                    kinase, phosphomevalonate kinase, mevalonate decarbox-
onate pathway synthesis IPP, GAP-pyruvate                       ylase (41). oxidoreductases exhibit high order
pathway organisms. S. aureus                      coenzyme specificity, oxidoreductases use mvaA null mutant severely attenuated mouse                             NADP(H) NAD(H) include L-glutamate dehydrogenase
hematogenous pyelonephritis infection model.                         (11, 12, 28), isocitrate dehydrogenase (13, 25), glucose-6-phos-
plasma mevalonate concentration mice mea-                         phate dehydrogenase (3, 5), 6-phosphogluconate dehydroge-
sured, concentrations humans rats, 0.02 0.08 â?®M                     nase (5), aldose reductase (30), biliverdin IXâ?£ reductase 0.08 0.50 â?®M, respectively (32),                       (26). exception liver alcohol dehydrogenase (2),
required support growth mvaA null mutant.                           coenzyme Km values 1 orders magnitude lower
   Derived sequence similarities conservation known                        NADP(H) NAD(H), suggesting preference active-site residues motifs (Fig. 5) suggested mvaA                  NADPH. HMG-CoA reductases  fulgidus S.
gene S. aureus encodes class II HMG-CoA reductase (41).                      aureus mere handful oxidoreductases, Expression E. coli mvaA-polyhistidine tag construct                      HMG-CoA reductases, Km essentially subsequent purification enzymatic characteriza-                       coenzyme.
tion gene product revealed case.                     Ki inhibition S. aureus HMG-CoA reductase Inspection pH profiles catalysis reactions                 statin drug 4 orders magnitude higher Ki revealed functional groups pKa values 7                      class eukaryotic enzyme, suggesting classes 9 protonated states activity. pro-                    discriminated chemically. recent publication pose His378 S. aureus (His378S) Lys263S                     crystal structure catalytic portion human HMG-
(Fig. 5), apparent cognates active-site residues His381                 CoA reductase (18) confirms large differences architec-
P. mevalonii (His381P) Lys267P P. mevalonii HMG-CoA                        ture active sites human P. mevalonii enzymes.
5152        WILDING ET AL.                                                                                                                                 J. BACTERIOL.

  agents selective inhibition class II bacterial                           map pE194, plasmid specifies inducible resistance macrolide,
enzymes achievable. essential nature                                  lincosamide, streptogramin type B antibiotics. J. Bacteriol. 150:804â€“814.
                                                                                        18.   Istvan, E. S., M. Palnitkar, S. K. Buchannan, J. Deisenhofer. 2000.
zyme suggests class II HMG-CoA reductases repre-                                     Crystal structure catalytic portion human HMG-CoA reductase:
sent promising target antibacterial agents directed                             insights regulation activity catalysis. EMBO J. 19:819â€“830.
multidrug-resistant gram-positive cocci.                                                19.   Johnson, E. , W.  Schroeder. 1996. Microbial carotenoids. Adv.
                                                                                              Biochem. Eng. Biotechnol. 53:119â€“178.
                                                                                        20.   Jordan-Starck, T. C., V. W. Rodwell. 1989. Pseudomonas mevalonii
                           ACKNOWLEDGMENTS                                                    3-hydroxy-3-methylglutaryl-CoA reductase characterization chemical
                                                                                              modification. J. Biol. Chem. 264:17913â€“17918.
   E. Imogen Wilding Dong-Yul Kim contributed equally                                                                                         21.   Khan, S., R. P. Novick. 1983. Complete nucleotide sequence pT181,
work.                                                                                         tetracycline-resistance plasmid Staphylococcus aureus. Plasmid 10:
   Purdue contribution funded National Institutes                               251â€“259.
Health grants HL 47113 (V.W.R.) 52115 (C.V.S.). SmithKline                      22.   Kim, D.-Y., D.  Bochar, C. V. Stauffacher, V. W. Rodwell. 1999.
Beecham contribution funded DARPA grant N65236-                                Expression characterization HMG-CoA reductase thermo-
97-1-5810.                                                                                    philic archaeon Sulfolobus solfataricus. Protein Exp. Purif. 17:435â€“442.
   SmithKline Beecham thank Chantal Petit Howard                            23.   Kim, D.-Y., C. V. Stauffacher, V. W. Rodwell. 2000. Expression Kallender helpful suggestions manuscript, Christopher                        characterization class II HMG-CoA reductase hyperthermo-
Traini, Thomas Mathie, Stephanie van Horn synthesis                            philic archaeon Archaeoglobus fulgidus. Protein Sci. 9:1226â€“1234.
                                                                                        24.   Lawrence, C. M., V. W. Rodwell, C. V. Stauffacher. 1995. Crystal struc-
oligonucleotides sequencing plasmid constructs, Nicole                             ture Pseudomonas mevalonii HMG-CoA reductase 3.0 angstrom reso-
Robertson Dean McNulty matrix-assisted laser desorption                               lution. Science 268:1758â€“1762.
ionization mass spectral N-terminal sequence analysis.                              25.   Leyland, M. L., D. J. Kelly. 1991. Purification characterization                                                                                               monomeric isocitrate dehydrogenase dual coenzyme specificity                                   REFERENCES                                                  photosynthetic bacterium Rhodomicrobium vannielii. Eur. J. Biochem. 202:
 1. Alberts,  W., J. Chen, G. Kuron, V. Hunt, J. Huff, C. Hoffman, J. Rothrock,             85â€“93.
    M. Lopez, H. Joshua, E. Harris,  Patchett, R. Monaghan, S. Currie, E.             26.   Maines, M. D., B. V. Polevoda, T. J. Huang, W. K. McCoubrey, Jr. 1996.
    Stapley, G. Albers-Schonberg, O. Hensens, J. Hirshfield, K. Hoogsteen, J.                 Human biliverdin IXâ?£ reductase zinc-metalloprotein. Characterization     Liesch, J. Springer. 1980. Mevinolin: highly potent competitive inhib-              purified Escherichia coli expressed enzymes. Eur. J. Biochem. 235:372â€“381.
    itor hydroxymethylglutaryl-coenzyme reductase cholesterol-low-           27.   Marmur, J. 1961. procedure isolation deoxyribonucleic acid
    ering agent. Proc. Natl. Acad. Sci. USA 77:3957â€“3961.                                     micro-organisms. J. Mol. Biol. 3:208â€“218.
 2. al-Kassim, L. S., C. S. Tsai. 1993. Purification kinetic characteriza-      28.   Maulik, P., S. Ghosh. 1986. NADPH/NADH-dependent cold-labile
    tion pickerel liver alcohol dehydrogenase dual coenzyme specificity.              glutamate dehydrogenase Azospirillum brasilense. Purification prop-
    Biochem. Cell Biol. 71:421â€“426.                                                           erties. Eur. J. Biochem. 155:595â€“602.
 3. Anderson, B. M., C. D. Anderson. 1995. Purification characteriza-           29.   Meganathan, R. 1996. Biosynthesis isoprenoid quinones menaquinone
    tion Azotobacter vinelandii glucose-6-phosphate dehydrogenase: dual                 (vitamin K2) ubiquinone (coenzyme Q), p. 642â€“656. F. C. Neidhardt,
    enzyme specificity. Arch. Biochem. Biophys. 321:94â€“100.                                   R. Curtiss III, J. L. Ingraham, E. C. C. Lin, K. B. Low, B. Magasanik, W. S.
 4. Beach, M. J., V. W. Rodwell. 1989. Cloning, sequencing, overex-                   Reznikoff, M. Riley, M. Schaechter, H. E. Umbarger (ed.), Escherichia
    pression mvaA, encodes Pseudomonas mevalonii 3-hydroxy-3-meth-                   coli Salmonella: cellular molecular biology, 2nd ed., vol. 1. American
    ylglutaryl coenzyme reductase. J. Bacteriol. 171:2994â€“3001.                             Society Microbiology, Washington, D.C.
 5. Ben-Bassat, ,  Goldberg. 1980. Purification properties glu-          30.   Neuhauser, W. D., D. Haltrich, K. D. Kulbe, B. Nidetzky. 1997.
    cose-6-phosphate dehydrogenase (NADPâ«¹/NADâ«¹) 6-phosphogluco-                           NAD(P)H-dependent aldose reductase xylose-assimilating yeast
    nate dehydrogenase (NADPâ«¹/NADâ«¹) methanol-grown Pseudomonas                           Candida tenuis. Isolation, characterization biochemical properties     C. Biochim. Biophys. Acta 611:1â€“10.                                                       enzyme.